Editas' share price has struggled due to clinical setbacks, but recent focus on in-vivo gene editing offers renewed hope and upside potential. The company is valued near cash levels, with $221M on ...

Liverpool’s Pursuit of Alexander Isak: Ambitious or Unrealistic? Liverpool’s ambitions in the summer market are as bold as ever following a Premier League title in Arne Slot’s debut season. With deals ...

Maxine Aubin: I asked the question directly to Victor Wembanyama. Here's the exchange: "Do we lack stats to evaluate the full extent of your defensive impact? — We might have too many offensive data ...